Prudential Financial Inc
Change company Symbol lookup
Select an option...
PRU Prudential Financial Inc
T AT&T Inc
VZ Verizon Communications Inc
CSPI CSP Inc
BXMT Blackstone Mortgage Trust Inc
PSNL Personalis Inc
PS Pluralsight Inc
POR Portland General Electric Co
PHI PLDT Inc
PD PagerDuty Inc
Go

Financials : Insurance | Large Cap Value
Company profile

Prudential Financial, Inc., is a financial services company. The Company, through its subsidiaries, offers a range of financial products and services, which includes life insurance, annuities, retirement-related services, mutual funds and investment management. The Company's operations consists of four divisions, which together encompass seven segments. The U.S. Retirement Solutions and Investment Management division consists of Individual Annuities, Retirement and Asset Management segments. The U.S. Individual Life and Group Insurance division consists of Individual Life and Group Insurance segments. The International Insurance division consists of International Insurance segment. The Closed Block division consists of Closed Block segment. The Company has operations in the United States, Asia, Europe and Latin America.

Price
Delayed
$60.94
Day's Change
-1.02 (-1.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
62.03
Day's Low
60.16
Volume
(Heavy Day)

Today's volume of 1,728,699 shares is on pace to be much greater than PRU's 10-day average volume of 2,512,205 shares.

1,728,699

Government to test remdesivir with Lilly drug in COVID-19 patients

2:46 pm ET May 8, 2020 (MarketWatch)
Print

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s (GILD) remdesivir in combination with Eli Lilly & Co.'s (LLY) rheumatoid arthritis drug Olumiant in COVID-19 patients as part of the next phase of the randomized, controlled clinical trial that led to the authorization of remdesivir (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01). This study will enroll 1,000 people at more than 100 sites in the U.S. and abroad, to "examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients," NIAID director Dr. Anthony Fauci said in a statement. The topline results from the remdesivir trial helped make up the basis of the Food and Drug Administration's (FDA) emergency use authorization for the drug last week. A number of medicines that have been previously approved by the FDA to treat rheumatoid arthritis have been proposed as possible COVID-19 treatments (http://www.marketwatch.com/story/covid-19-treatment-yields-disappointing-data-in-trial-and-shows-its-not-easy-to-develop-drugs-2020-04-28), including Regeneron Pharmaceuticals Inc. (REGN) and Sanofi's (SAN.FR) Kevzara and Roche Holding AG's Actemra. Olumiant, which was developed by Incyte Corp. (INCY) and is licensed to Lilly, brought in $427 million in sales in 2019 for the Indianapolis-based drugmaker. Only two types of therapies - remdesivir and hydroxycholorquine and chlorquine - are authorized by the FDA as COVID-19 treatments. Year-to-date, Gilead's stock has gained 18.6%, while shares of Lilly are up 16.6%. The S&P 500 is down 10.8%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 08, 2020 14:46 ET (18:46 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.